Literature DB >> 9496730

Soluble P-selectin is released from activated platelets in vivo during hemodialysis.

K Kawabata1, Y Nagake, K Shikata, S Fukuda, H Nakazono, M Takahashi, H Ichikawa, H Makino.   

Abstract

During hemodialysis, platelets are activated across a dialyzer. Soluble P-selectin (sP-selectin) is a form of P-selectin which is a glycoprotein relocated from secretory granules to the surfaces of platelets and endothelial cells after these cells have been physiologically activated. To investigate whether sP-selectin is useful as a marker of platelet activation during hemodialysis, we measured the plasma concentration of sP-selectin by enzyme-linked immunosorbent assay in 6 patients hemodialyzed in our institute using regenerated cellulose (RC) membranes and thereafter polysulfone membranes. Concomitantly, we also measured the plasma concentration of platelet factor 4 and beta-thromboglobulin which are released from alpha-granules of activated platelets. During hemodialysis with RC membranes, the beta-thromboglobulin level was significantly increased 15 min (p < 0.05) and the sP-selectin level 15 (p < 0.05) and 180 min (p < 0.05) after initiation of dialysis on the venous side as compared with the arterial side of the hemodialyzer. During hemodialysis with polysulfone membranes, no significant variation in plasma beta-thromboglobulin and sP-selectin levels was detected. The platelet factor 4 level increased more significantly across a dialyzer 180 min after initiation of dialysis with RC than with polysulfone membranes (p < 0.01). The changes in plasma platelet factor 4 and beta-thromboglobulin levels demonstrated that platelets are more activated during hemodialysis with RC than with polysulfone membranes. The changes in plasma sP-selectin levels during hemodialysis with RC confirm that the release of P-selectin purely from activated platelets was detected by enzyme-linked immunosorbent assay. sP-selectin may be a marker of platelet activation during hemodialysis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9496730     DOI: 10.1159/000044903

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  7 in total

1.  CD62P and P10 as predictive markers for assessing the efficacy of hemodialysis in treating end-stage renal disease.

Authors:  Ji-Rong Yu; Feng-Mei Wang; Sheng-Chun Xu; Min Gao
Journal:  J Clin Lab Anal       Date:  2018-10-15       Impact factor: 2.352

2.  Plasma level of soluble P-selectin in patients with rheumatic mitral stenosis and sinus rhythm undergoing percutaneous mitral balloon valvuloplasty.

Authors:  Serkan Topaloglu; Dursun Aras; Kumral Ergun; Bilal Geyik; Selime Ayaz; Serkan Cay; Goksel Cagirci; Omac Tufekcioglu; Sule Korkmaz
Journal:  J Thromb Thrombolysis       Date:  2006-11-28       Impact factor: 2.300

3.  Acetate-free blood purification can impact improved nutritional status in hemodialysis patients.

Authors:  Kazuhiro Matsuyama; Tadashi Tomo; Jun-ichi Kadota
Journal:  J Artif Organs       Date:  2011-02-19       Impact factor: 1.731

4.  Assessment of wound healing efficacy of Growth Factor Concentrate (GFC) in non-diabetic and diabetic Sprague Dawley rats.

Authors:  Manohar Nandanwar; Vijay Sharma; Avinash Karade; Anuka Sharma; Atul Kansagara; Ulka Sakhalkar; Yasmeen Sidhu; Sangita Gupta; Muftedar Patel; Parag Ghorpade
Journal:  J Diabetes Metab Disord       Date:  2021-09-27

5.  Endogenous bradykinin contributes to increased plasminogen activator inhibitor 1 antigen following hemodialysis.

Authors:  Annis M Marney; Ji Ma; James M Luther; T Alp Ikizler; Nancy J Brown
Journal:  J Am Soc Nephrol       Date:  2009-07-23       Impact factor: 10.121

6.  Use of a polysulfone hemodialysis membrane may prevent recurrent posterior reversible encephalopathy syndrome in a patient undergoing hemodialysis.

Authors:  Akira Mima; Takeshi Matsubara; Shuichiro Endo; Taichi Murakami; Yasuki Hashimoto
Journal:  Int Urol Nephrol       Date:  2013-04-09       Impact factor: 2.370

7.  Platelet activity and hypercoagulation in type 2 diabetes.

Authors:  Lesha Pretorius; Greig J A Thomson; Rozanne C M Adams; Theo A Nell; Willem A Laubscher; Etheresia Pretorius
Journal:  Cardiovasc Diabetol       Date:  2018-11-02       Impact factor: 9.951

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.